Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis

ClinicalTrials.gov ID: NCT04506463

Public ClinicalTrials.gov record NCT04506463. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 9:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Single-administration, Multiple-Dose Study to Demonstrate the Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis

Study identification

NCT ID
NCT04506463
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Enrollment
397 participants

Conditions and interventions

Interventions

  • MM-II dose I Drug
  • MM-II dose II Drug
  • MM-II dose III Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
40 Years to 99 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 21, 2020
Primary completion
May 3, 2022
Completion
Aug 9, 2022
Last update posted
Aug 28, 2024

2020 – 2022

United States locations

U.S. sites
21
U.S. states
10
U.S. cities
18
Facility City State ZIP Site status
Sunpharma site no. 20 Birmingham Alabama 35209
Sunpharma site no. 11 Tempe Arizona 85283
Sunpharma site no. 25 Riverside California 92503
Sunpharma site no. 26 San Diego California 92103
Sunpharma site no. 06 Stamford Connecticut 06905
Sunpharma site no. 10 Lady Lake Florida 32159
Sunpharma site no. 08 Lake Worth Florida 33461
Sunpharma site no. 13 Maitland Florida 32751
Sunpharma site no. 22 Miami Florida 33145
Sunpharma Site no 27 Miami Florida 33155
Sunpharma site no. 12 Miami Florida 33155
SunPharma Site no 23 Miami Florida 33176
Sunpharma site no. 05 Sunrise Florida 33351
Sunpharma site no. 04 The Villages Florida 32159
Sunpharma site no. 18 Flossmoor Illinois 60422
Sunpharma site no. 07 Hazelwood Missouri 63042
Sunpharma site no. 17 Williamsville New York 14221
Sunpharma site no. 19 Edmond Oklahoma 73013
Sunpharma site no. 09 Charleston South Carolina 29406
SunPharma Site No 24 Columbia South Carolina 29206
Sunpharma site no. 21 Fort Mill South Carolina 29707

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04506463, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 28, 2024 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04506463 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →